ABSTRACT
INTRODUCTION
The use of antithymocyte globulin as a single therapy or in combination with cyclosporinandcorticosteroidshaschanged thenaturalhistoryofsevereaplasticanemia inpatientswhodonothaveabonemarrow donor.Today, antithymocyte globulin is a usefultherapeutictoolwitharesponserateof 40-80%.However,despitetheimprovements achievedbyusingandrogens,corticosteroids, cyclosporin and/or antithymocyte globulin, some quantitative abnormalities remain in all hematopoietic cell lines, thus suggesting thataplasticanemiahasnotbeencompletely eliminated.1
Relationships have been described be-tween aplastic anemia and acute leukemia, and with other clonal disorders such as paroxysmal nocturnal hemoglobinuria and myelodysplasticsyndrome.Theevolutionof aplasticanemiatomyelodysplasticsyndrome oracuteleukemiawasconsideredtoberare (1-3%)instudiesdatingfromthelate1950sto the1970s,althougha57%riskofdeveloping hematologicalcomplicationsatatimeofeight yearsafterantithymocyteglobulintherapywas reportedin1988.2Wereportacaseofaplastic
anemiawithacquiredhemoglobinHdisease evolvingintomyelodysplasticsyndromeand leukemia.
CASEREPORT
A 36-year-old man presented with a 4-monthhistoryofpallorandfatigue.Hehad beenworkingasmechanicfor10yearswith frequentbenzeneexposure.Uponadmission,
hewaspale,afebrileandhispulseratewas100 beats/min.Theperipheralbloodcellcount showed hemoglobin concentration of 2.8 g/dl,hematocritof9%,meancorpuscular volumeof82fl,meancorpuscularhemo-globin mass of 27 pg, mean corpuscular hemoglobinconcentrationof33g/dl,white bloodcellcountof1.8X109/l,andplatelet
countof5x106/l.Thereticulocytecountwas
1%andHam’stestwasnegative.Thebone marrowaspirateshowedsignificanthypocellu-larmarrowwithoutdyserythropoieticfeatures andthebonemarrowbiopsywasinconclusive. Hewastreatedwithprednisoneandandrogens (oxymetholone), which led to gradual im-provementintheperipheralbloodcellcount, withlowplateletcount(45x106/l).
Aftertwoyearsoffollow-up,thepatient maintained the same hematological pattern withoutfurthertreatment.Asecondbiopsy showedhypocellularmarrowwitherythroid hyperplasia.
Three years later, he complained of symptoms due to anemia. His hemoglobin concentrationwas9.6g/dl,withhematocrit of30%,meancorpuscularvolumeof80fl, meancorpuscularhemoglobinconcentration of28g/dlandreticulocytecountof10.2%. Erythrocyteinclusionsof“golf-ball”pattern, typical of hemoglobin H, were seen. He-moglobin electrophoresis demonstrated the presenceofhemoglobinH,withraisedfetal hemoglobin of 8.4%. Bone marrow aspira-tionwasagainperformed,showingerythroid hyperplasia, dyserythropoiesis with normal ironstoresandabsenceofringsideroblasts. The sucrose hemolysis test and Ham’s test werenegative.
C
aseR
epor
t
•MariaStellaFigueiredo
•PerlaVicari
•ElizaYurikoSuganoKimura
•SandraVallinAntunes
•MihokoYamamoto
AcquiredhemoglobinH
diseaseinapatientwith
aplasticanemiaevolvinginto
acutemyeloidleukemia
DisciplineofHematologyandHemotherapy,UniversidadeFederaldeSão
Paulo–EscolaPaulistadeMedicina,SãoPaulo,Brazil
CONTEXT:Theprognosisofsevereaplasticanemia has improved since the introduction of bone marrowtransplantationandtreatmentwithanti-thymocyteglobulin.Incontrasttothesuccessof theseprotocols,studieswithlongtermfollow-up haveshowntheoccurrenceofclonaldiseases suchasparoxysmalnocturnalhemoglobinuria, myelodysplasticsyndromeandacuteleukemia inaplasticanemia.
CASEREPORT: WereportthefirstcaseofaBrazil-ianpatientwithaplasticanemiawhodeveloped myelodysplastic syndrome and acute myeloid leukemiashowingacquiredhemoglobinHand increasedfetalhemoglobin.
KEY WORDS: Hemoglobin H. Disease. Aplastic anemia. Myeloid leukemia. Myelodysplastic syndromes.
SãoPauloMedicalJournal—RevistaPaulistadeMedicina
274
Tenmonthslater,hewasadmittedwith severeanemia(hemoglobinof4.3g/dl).The bone marrow aspirate demonstrated a blast cellconcentrationof64%,andadiagnosisof acutemyeloidleukemiawasmade(Figure1). This was confirmed by immunophenotyp-ing,butnocytogeneticstudywasperformed. Induction therapy with daunorubicin and cytosinearabinosidewasinitiated,butremis-sionwasnotachieved.Hediedafterasecond course of chemotherapy due to intracranial hemorrhage.
DISCUSSION
Improvementsinthetreatmentofaplastic anemiabymeansofbonemarrowtransplanta-tion,andtheuseofantithymocyteglobulin and/or cyclosporin, have raised the survival rateforthisdiseasefrom60%to90%but,at thesametime,theriskoflateclonalhemato-logicalcomplicationshasincreased.1-3
Fewcasesofaplasticanemiacasesdevelop- ingwithacutemyeloidleukemiaormyelodys-plastic syndrome have been reported in the literature.1-3Ontheotherhandithaslongbeen
commonlyknownthatmyelotoxicagents,such as radiation and benzene, can cause aplastic anemiaaswellasacuteleukemia.
Hemoglobin synthesis disorders are frequentlyobservedinthepresenceofclonal erythropoiesis. It has been suggested that
disordered gene regulation is a common feature of transformed cells, and that this canbemanifestedeitherbythesynthesisof aninappropriategeneproduct,suchasfetal hemoglobin synthesis, or by the loss of an appropriateproduct,suchasdeficientproduc-tionofanα-globinchainresultinginacquired hemoglobinH.4
Persistenceorreactivationoffetalhemo-globinsynthesishasgenerallybeenassociated with certain dyserythropoietic conditions, such as allogenic stem cell transplantation, aplasticanemia,paroxysmalnocturnalhemo-globinuria,myelodysplasticsyndromeoracute myeloidleukemia.However,themechanism forfetalhemoglobinuriasynthesisisunknown and the clinical value of fetal hemoglobin levels under these conditions remains con-troversial.4
There is a clear association between acquired hemoglobin H disease and clonal hematopoiesis, but frequency of such an association is unknown, probably because reticulocyte preparations are not set up or adequately examined for the presence of hemoglobinHinclusions.4
Molecularstudiesofacquiredhemoglo-bin H disease have shown the presence of structurallynormalα-globingenesbutwith decreased expression. It is not completely clear whether the presence of hemoglobin Hisamarkerforaparticularsubgroupof
myeloproliferative disorders or whether it is a secondary event that may develop in neoplasticcells.5
A clear distinction between aplastic anemia and hypoplastic myelodysplastic syndrome must always be made, because theyhavedifferentrisksofdevelopingwith acute myeloid leukemia: 9% for patients withaplasticanemiaand83%forthosewith myelodysplasticsyndrome.6Inourcase,the
bonemarrowbiopsieswerenothelpfulinan-sweringthisquestion.However,ourpatient presented rapid improvement in hemato-poiesis,upontherapy.Moreover,hedidnot needtransfusionfor5years.Alltheseaspects support the hypothesis of aplastic anemia. After this period, he presented dyshema-topoietic abnormalities and, subsequently, acutemyeloidleukemia.
Tichellietal.2observedthatrapidrecovery
ofthebonemarrowafteraplasticanemiais themostpredictiveriskfactorfortransforma-tionintoleukemia.Althoughthesedysplastic alterationsaremostprominentbetween3and 6monthsaftertreatment,theymaydisappear andthebonemarrowmorphologymaylook normal for varying periods of time before leukemiaoccurs.2
Nowadays,aplasticanemiaisconsidered to be a monoclonal disease that sometimes isanearlymanifestationofmyelodysplastic syndromeoracutemyeloidleukemia.1Some
studies have demonstrated the presence of monoclonalhematopoiesisin72%ofpatients withaplasticanemia.2,3,6Nevertheless,itisnot
known whether clonal hematopoiesis could haveaprognosticvalueinaplasticanemia.
Finally, the appearance of late hemato-logicalcomplicationsinpatientswithaplastic anemiaraisesthequestionofwhethermyelo-dysplastic syndrome, paroxysmal nocturnal hemoglobinuriaandaplasticanemiaarejust differentmanifestationsofthesamedisease. Wesuggestthataplasticanemiaandacquired hemoglobinHdiseasecouldbeconsideredto betwostepsintheneoplastictransformation ofthepluripotentstemcell.
SaoPauloMedJ.2004;122(6):273-5
SãoPauloMedicalJournal—RevistaPaulistadeMedicina
275
C
aseR
epor
t
1. TamuraS,KanamaruA,TakemotoY,KakishitaE,NagaiK. Clonalevolutionsduringlong-termculturesofbonemarrow fromdenovoacutemyeloidleukaemiawithtrilineagemyelo-dysplasia and with myelodysplastic remission marrow. Br J Haematol.1993;84(2):219-26.
2. TichelliA,GratwohlA,WurschA,NissenC,SpeckB.Late haematologicalcomplicationsinsevereaplasticanaemia.BrJ
Haematol.1988;69(3):413-8.
3. SociéG,RosenfeldS,FrickhofenN,GluckmanE,TichelliA. Lateclonaldiseasesoftreatedaplasticanemia.SeminHematol. 2000;37(1):91-101.
4. KudoS,HarigaeH,WatanabeN,etal.IncreasedHbFlevelsin dyserythropoiesis.ClinChimActa.2000;291(1):83-7. 5. AnninoL,DiGiovanniS,TentoriL,etal.Acquiredhemoglobin
Hdiseaseinacaseofrefractoryanemiawithexcessofblasts (RAEB) evolving into acute nonlymphoid leukemia. Acta Haemat.1984;72(1):41-4.
6. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or dis-easeslinkedbyacommonpathophysiology?SeminHematol. 2000;37(1):15-29.
PUBLISHINGINFORMATION
MariaStellaFigueiredo,MD,PhD. DisciplineofHe-matologyandHemotherapy,UniversidadeFederaldeSão Paulo—EscolaPaulistadeMedicina,SãoPaulo,Brazil.
PerlaVicari,MD. DisciplinadeHematologiaeHemotera-pia,UniversidadeFederaldeSãoPaulo—EscolaPaulista deMedicina,SãoPaulo,Brazil.
Eliza Yuriko Sugano Kimura, BSc.Discipline of Hematology and Hemotherapy, Universidade Federal de São Paulo — Escola Paulista de Medicina, São Paulo,Brazil.
Sandra Vallin Antunes, MD, PhD.Discipline of Hematology and Hemotherapy, Universidade Federal de São Paulo — Escola Paulista de Medicina, São Paulo,Brazil.
Mihoko Yamamoto, MD, PhD.Discipline of He-matology and Hemotherapy, Universidade Federal de São Paulo — Escola Paulista de Medicina, São Paulo,Brazil.
Sourcesoffunding:None
Conflictofinterest:None
Dateoffirstsubmission:February14,2003
Lastreceived:July13,2004
Accepted:July15,2004
Addressforcorrespondence:
MariaStellaFigueiredo
DisciplinadeHematologia—UniversidadeFederal deSãoPaulo—EscolaPaulistadeMedicina R.Botucatu,740—3oandar
SãoPaulo(SP)—Brasil—CEP04223-900 Tel./Fax.(+5511)5571-8806 E-mail:stella@hemato.epm.br
COPYRIGHT©2004,AssociaçãoPaulistadeMedicina
HemoglobinopatiaHadquiridaemumpaciente comanemiaaplásticaeevoluçãoparaleu-cemiamielóideaguda
CONTEXTO:
Oprognósticodaanemiaaplás-tica grave melhorou com o advento do transplantedemedulaósseaedotratamento imunossupressor com globulina antitimo-citária.Emcontrastecomosucessodestes protocolos, os estudos com seguimento a longo prazo mostraram a ocorrência de
doençasclonais,taiscomo:hemoglobinúria paroxísticanoturna,síndromemielodisplá-sicaeleucemiaaguda.
RELATODECASO:Nósrelatamosoprimeiro
casodescritonoBrasildeumpacientecom anemiaaplásticaqueevoluiuparasíndrome mielodisplásica e leucemia mielóide aguda associada a presença de hemoglobina H e aumentodahemoglobinafetal.
PALAVRAS CHAVES: Doença. Hemoglobina
H. Anemia aplástica. Leucemia mielóide. Síndromesmielodisplásicas.
REFERENCES
RESUMO